These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 2883877)

  • 1. Role of cardioselectivity and intrinsic sympathomimetic activity in beta-blocking drugs in chronic coronary artery disease.
    DiBianco R
    Am J Cardiol; 1987 May; 59(13):38F-43F. PubMed ID: 2883877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of cardioselectivity and intrinsic sympathomimetic activity in beta-blocking drugs in cardiovascular disease.
    Taylor SH
    Am J Cardiol; 1987 May; 59(13):18F-20F. PubMed ID: 2883872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of intrinsic sympathomimetic activity of beta-adrenoceptor blocking drugs in the treatment of patients with angina pectoris.
    Harry JD
    Bibl Cardiol; 1976; (35):172-82. PubMed ID: 10882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous beta-blockade in coronary heart disease: is cardioselectivity or intrinsic sympathomimetic activity hemodynamically useful?
    Taylor SH; Silke B; Lee PS
    N Engl J Med; 1982 Mar; 306(11):631-5. PubMed ID: 6120457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antihypertensive effects of 12 beta adrenoceptor antagonists in conscious spontaneously hypertensive rats: relationship to changes in plasma renin activity, heart rate and sympathetic nerve function.
    Antonaccio MJ; High J; DeForrest JM; Sybertz E
    J Pharmacol Exp Ther; 1986 Jul; 238(1):378-87. PubMed ID: 2873238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ancillary pharmacologic properties of acebutolol: cardioselectivity, partial agonist activity, and membrane-stabilizing activity.
    Giacomini JC; Thoden WR
    Am Heart J; 1985 May; 109(5 Pt 2):1137-44. PubMed ID: 2859777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pharmacological basis for the therapy of cardiovascular disease with beta-adrenoceptor blocking drugs (author's transl)].
    Lemmer B
    Herz; 1982 Jun; 7(3):168-78. PubMed ID: 6124492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Haemodynamic effects of intravenous beta-blocking drugs in coronary heart disease.
    Taylor SH; Silke B; Nelson GI
    J Pharmacol; 1983; 14 Suppl 2():157-67. PubMed ID: 6138465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beta adrenergic blocking agents for exertional angina pectoris.
    Thadani U
    Herz; 1982 Jun; 7(3):179-87. PubMed ID: 6124493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beta-blocking drugs for arrhythmias, hypertension, and ischemic heart disease.
    Johns VJ
    Am J Surg; 1984 Jun; 147(6):725-30. PubMed ID: 6145367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 6. A comparison of pindolol and propranolol in treatment of patients with angina pectoris. The role of intrinsic sympathomimetic activity.
    Frishman W; Kostis J; Strom J; Hossler M; Elkayam U; Goldner S; Silverman R; Davis R; Weinstein J; Sonnenblick E
    Am Heart J; 1979 Oct; 98(4):526-35. PubMed ID: 39447
    [No Abstract]   [Full Text] [Related]  

  • 12. [Beta-blockers in effort angina].
    Witchitz S; Kolsky H; Moisson P; Philippe B
    Arch Mal Coeur Vaiss; 1983 Feb; 76 Spec No():87-95. PubMed ID: 6134513
    [No Abstract]   [Full Text] [Related]  

  • 13. Beta-blocking drugs and coronary heart disease.
    Goldstein S
    Cardiovasc Drugs Ther; 1997 May; 11 Suppl 1():219-25. PubMed ID: 9211014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intrinsic sympathomimetic activity: clinical fact or fiction?
    Taylor SH
    Am J Cardiol; 1983 Nov; 52(9):16D-26D. PubMed ID: 6139009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of beta-adrenergic blockers in the treatment of angina and hypertension.
    Caris TN
    Angiology; 1986 Mar; 37(3 Pt 2):215-7. PubMed ID: 2871779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical relevance of intrinsic sympathomimetic activity of beta blockers.
    Kostis JB; DeFelice EA; Frishman W; Hosler M; Krieger SK; Aglitz N; Kuo PT
    Angiology; 1981 Nov; 32(11):780-7. PubMed ID: 6119937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic and pharmacodynamic properties of beta-blocking drugs influencing choice in treatment of systemic hypertension.
    Harrison DC
    Am J Cardiol; 1987 Sep; 60(9):13E-16E. PubMed ID: 2889349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative haemodynamic dose-response effects of intravenous propranolol, acebutolol and penbutolol in angina pectoris.
    Silke B; Nelson GI; Verma SP; Ahuja RC; Okoli RC; Hussain M; Taylor SH
    Herz; 1984 Feb; 9(1):57-64. PubMed ID: 6368345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beta-adrenoceptor blockade and intrinsic sympathomimetic activity--relevance in the treatment of ischaemic heart disease.
    Northcote RJ; Ballantyne D
    Scott Med J; 1985 Oct; 30(4):208-15. PubMed ID: 2869581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Intrinsic sympathomimetic activity with beta-receptor blockers. Significance for differential therapy (author's transl)].
    Noack E
    MMW Munch Med Wochenschr; 1982 Apr; 124(15):377-80. PubMed ID: 6123078
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.